Close Menu

NEW YORK – T2 Biosystems on Tuesday announced preliminary fourth quarter revenues of $7.8 million late Tuesday, representing growth of 155 percent over $3.1 million in the year-ago quarter but below the consensus Wall Street estimate of $8.7 million. 

The firm also announced that it has amended the terms of a loan agreement with CRG, a global healthcare investor.

Product revenues for T2 in the fourth quarter were up 274 percent to $5.8 million, the Lexington, Massachusetts-based firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.